Navigation Links
Kuvan Receives Positive Opinion From CHMP for European Approval
Date:9/25/2008

Decision on Marketing Authorization Expected by End of 2008

NOVATO, Calif., Sept. 25 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has received a positive opinion for Kuvan(R) (sapropterin dihydrochloride) as an oral treatment for hyperphenylalaninemia (HPA) in patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA). The CHMP recommendation will be considered by the European Commission, which will deliver its final decision on the granting of marketing authorization within 67 days.

"The positive opinion from the CHMP is encouraging and bodes well for potential approval, which is on track by the end of the year, triggering a $30 million milestone payment to BioMarin," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We are excited to work with our partner Merck Serono to offer the first therapeutic option to manage PKU in the European market."

About Kuvan

Kuvan(R) (sapropterin dihydrochloride) Tablets is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.

The active ingredient in Kuvan, sapropterin dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe. BioMarin and Merck Serono estimate that Kuvan could be a potent
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
2. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
3. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
4. Sustainable Oils Receives Regulatory Approval for Feeding Camelina Meal in Livestock Diets
5. U.S. Genomics Inc. Receives $4.5 Million Investment from BD
6. AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM)
7. PLC Systems Receives Delisting Notice From American Stock Exchange
8. Nephros Receives Non-Compliance Notification from AMEX
9. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
10. Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules
11. Intact Medical Corporations Intact(R) Excise XL Receives 510(K) Marketing Clearance from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 Vestiage, Inc. (stock symbol ... on science-based research and development, sales and marketing ... nutraceuticals, announced today that it is awarding exclusive ... sale of Reluma Skin Illuminating Facial Care. Qualified ... by sending an email to info(at)vestiageinc(dot)com and putting ...
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. (Nasdaq: ... focused on obtaining FDA clearance and commercializing its rapid, ... the pricing of an underwritten public offering of 10,000,000 ... purchase 3,500,000 shares of its common stock at an ... public offering price of $1.25 per share and related ...
(Date:5/23/2013)... May 23, 2013 Patheon Inc ... services to the global pharmaceutical industry, will host a ... Approaches to Testing” on Tuesday, June 4, 2013 at ... manufacturers are required to comply with regulations for cleaning ... with limited scientific underpinning and little evaluation of risk. ...
(Date:5/23/2013)... MA (PRWEB) May 23, 2013 ... inch wide and provide 15 mm travel range ... The small dimensions make these new positioners ... confined spaces. A vacuum rated version is also ... Drawings, specifications and datasheets can be found at: ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2
... 1 PSKW, LLC, a New Jersey-based,leading provider ... today that it has significantly expanded the scope ... the Supreme Court of the State,of New York, ... Inc.,("McKesson"), a wholly-owned subsidiary of McKesson Corporation. PSKW ...
... China, Sept. 1 /Xinhua-PRNewswire-FirstCall/ -- China,Pharma Holdings, ... which,develops, manufactures, and markets generic and branded ... the Susquehanna Financial,Group, LLP (SIG)"Beijing Management Summit" ... the 12th of September 2008., Attending ...
... , With some 20,000 UK children with ... year, new guidance from the National Institute for ... the way children,manage their diabetes, granting more freedom ... insulin pump therapy. The new,recommendations finally acknowledge key ...
Cached Biology Technology:PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKesson's Patent Application 2British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 2British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 3British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 4
(Date:5/23/2013)... treating cerebral palsy with autologous cord blood. Following a ... old boy had been in a persistent vegetative state ... after treatment with the cord blood containing stem cells, ... child learned to speak simple sentences and to move. ... dispel the long-held doubts about the effectiveness of the ...
(Date:5/23/2013)... world,s largest and fastest growing open-access publishers, announces ... in Bioengineering and Biotechnology . , A ... in Bioengineering and Biotechnology will provide a ... and biotechnology research to be disseminated and discussed. ... will provide an open-science and interactive web ...
(Date:5/23/2013)... age when microbial pathogens are growing increasingly resistant to ... team of Wisconsin scientists has synthesized a potent new ... cause staph infections. , Writing online in the ... led by University of Wisconsin-Madison chemistry Professor Helen Blackwell ... behavior of Staphylococcus aureus , a bacterium at ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2University of Wisconsin chemists find new compounds to curb staph infection 2
... YORK Computed Tomography (CT) scans are an increasingly used ... organ or tissue. The value of CT scanning to diagnose ... these scans being used too frequently, in some cases unnecessarily" ... scans over the course of a persons life" In ...
... Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused ... diseases of aging, announced today that findings in the ... candidates that offer a promising, new approach to treating ... SIRT1, a gene that controls the aging process. ...
... of nanotechnologys potential risks growing" If so, ... newspapers and newswiresenvironmental and consumer organizations, scientists, law ... broadcast journalists decide to cover a nanotechnology story, ... and television correspondents face special challenges reporting on ...
Cached Biology News:Columbia researchers: Growth of CT scan use may lead to significant public health problem 2Columbia researchers: Growth of CT scan use may lead to significant public health problem 3Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging 2Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging 3Nanotechnology and the media: The inside story 2
... K-12 strain ideally suited as an initial ... efficiency, blue/white screening capability (with appropriate plasmids) ... high yields of excellent quality plasmid DNA. ... useful as a stringent host due to ...
... kit contains all the reagents required for ... c reductase activity in cell and tissue ... (ER)]. It has been tested on samples ... kidney, brain, spleen, and heart muscle from ...
... an automated, confocal, real-time, single cell kinetic ... integrated into a single, compact unit. ... high-resolution, automated confocal imaging with sophisticated imaging ... assays. The system allows the user to ...
... Invitrogen makes blotting of E-PAGE Gels easier ... fiber blotting pad and several types of ... fit 8.6 cm x 13.5 cm E-PAGE ... membranes are designed for western transfer of ...
Biology Products: